Impediments to Collaboration on HIV Drug and Vaccine Development: Defining the Issues

Discussion Leader: Patrick Gage, Chief Operating Officer, Genetics Institute, Inc.

Commentary from a Government/NIH Perspective

  • Bruce Chabner, Director, Division of Cancer Treatment, National Cancer Institute

A View from the Pharmaceutical Industry

  • Stephen Carter, Senior Vice President, World Wide Clinical Research & Development, Bristol-Myers Squibb Pharmaceutical Research Institute

Practical Implications of Rules Governing Intellectual Property Developed from Collaborative Relationships

  • Harold Edgar, Professor of Law, Columbia University School of Law






Overcoming Obstacles to Collaboration and Promoting HIV Drug and Vaccine Development: Proposals for Resolution

Discussion Leader: Martin Delaney, Founding Director, Project Inform

Industry Perspective

  • David Barry, Group Director, Research, Development and Medical Affairs, The Wellcome Research Laboratories

Government/NIH Perspective

  • Anthony Fauci, Director, National Institute of Allergy and Infectious Diseases

Congressional/Legislative Response

  • Timothy Westmoreland, Counsel, Subcommittee on Health and the Environment, U.S. House of Representatives

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement